SALT
LAKE CITY, Sept. 8, 2022 /PRNewswire/ --
PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company
developing regenerative tissue products and biomaterials, today
announced that Jeff Dyer, PhD, has
decided to resign from its Board of Directors, effective
immediately.
"On behalf of our Board and PolarityTE's management team, we
thank Jeff for his service and longstanding commitment to the
Company," stated Richard Hague,
Chief Executive Officer of PolarityTE. "We greatly appreciate
the leadership and insight that Jeff has provided over the past
five and a half years as we pursued the path that led to an IND
accepted by FDA for our product SkinTE® and the start of an
approved clinical trial in diabetic foot ulcers."
Dr. Dyer stated, "It has been an honor to serve as a director of
PolarityTE. Richard and his team have done an incredible job
advancing PolarityTE's IND application and clinical trial process.
Now that PolarityTE has settled into a well-defined
regulatory path and clinical trial process for SkinTE®, I believe
my time and talents may be better applied in other opportunities
and endeavors." Dr. Dyer went on to say, "I want to thank my
fellow directors and wish the Company nothing but success."
About PolarityTE®
PolarityTE, Inc., headquartered in
Salt Lake City, Utah, is a
biotechnology company developing regenerative tissue
products. PolarityTE's first regenerative tissue product is
SkinTE®. PolarityTE has an open investigational new drug
application (IND) for SkinTE® with the U.S. Food and Drug
Administration (FDA) and is now pursuing the first of two pivotal
studies on SkinTE® needed to support a biologics license
application (BLA). SkinTE® is available for investigational
use only. Learn more at www.PolarityTE.com.
Forward Looking Statements
Certain statements
contained in this release are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. They are generally identified by words such as "believes,"
"may," "expects," "anticipates," "intend," "plan," "will," "would,"
"should" and similar expressions. Readers should not place undue
reliance on such forward-looking statements, which are based upon
the Company's beliefs and assumptions as of the date of this
release. The Company's actual results could differ materially due
to the impact of the COVID-19 pandemic, future clinical studies,
and FDA regulatory matters, which cannot be predicted, and the risk
factors and other items described in more detail in the "Risk
Factors" section of the Company's Annual Reports and other filings
with the SEC (copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. The Company specifically disclaims any
obligation or intention to update or revise these forward-looking
statements as a result of changed events or circumstances that
occur after the date of this release, except as required by
applicable law.
POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES
SELF and WELCOME TO THE SHIFT are registered trademarks of
PolarityTE, Inc.
CONTACTS
Investors:
PolarityTE Investor Relations
ir@PolarityTE.com
385-831-5284
Media:
David Schull or
Ignacio Guerrero-Ros
David.schull@russopartnersllc.com
Ignacio.guerrero-ros@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/polarityte-announces-resignation-of-jeff-dyer-from-its-board-of-directors-301619900.html
SOURCE PolarityTE, Inc.
